Prevalence and significance of autoantibodies in children with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.
antinuclear antibodies
antismooth muscle antibodies
autoimmune hepatitis
fatty liver
Journal
Journal of pediatric gastroenterology and nutrition
ISSN: 1536-4801
Titre abrégé: J Pediatr Gastroenterol Nutr
Pays: United States
ID NLM: 8211545
Informations de publication
Date de publication:
05 Jul 2024
05 Jul 2024
Historique:
revised:
17
05
2024
received:
24
02
2024
accepted:
17
06
2024
medline:
5
7
2024
pubmed:
5
7
2024
entrez:
5
7
2024
Statut:
aheadofprint
Résumé
Significance of autoantibodies in pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is unknown. Our aim was to determine the prevalence and significance of autoantibodies in MASLD. PubMed and Scopus were searched and six articles (689 [487 males] MASLD patients) were identified. Antinuclear antibodies (ANA) was positive in 28% (95% confidence interval [CI]: 17%-39%, n = 6 studies), Antismooth muscle antibodies (ASMA) in 28% (95% CI: 8%-50%, n = 5 studies), Actin-positive in 15% (95% CI: 10%-20%, n = 2 studies) and elevated immunoglobulin G in 17% (95% CI: 1%-39%, n = 4 studies). Anti-liver-kidney-microsomal antibody was not present in any patient. There was no significant association of ANA positivity with degree of liver steatosis, liver fibrosis or nonalcoholic fatty liver disease activity score (NAS) but patients with ASMA positivity had advanced fibrosis (pooled risk ratio [RR] 1.77; 95% CI 1.16-2.71) and higher risk of NAS ≥5 (pooled RR 1.21; 95% CI: 1.01-1.44, n = 2 studies, 243 patients). To conclude, non-organ specific autoantibodies are present in over one-fourth of children with MASLD and the presence of ASMA maybe associated with increased disease severity.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : None
Informations de copyright
© 2024 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
Références
Li J, Ha A, Rui F, et al. Meta‐analysis: global prevalence, trend and forecasting of non‐alcoholic fatty liver disease in children and adolescents, 2000‐2021. Aliment Pharmacol Ther. 2022;56:396‐406.
Patton HM, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J, Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology. 2008;135(6):1961‐1971.e2.
Kohut T, Shah A, Russo P, Panganiban J. Autoimmune antibodies in children and adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2022;75(3):264‐268.
Khayat A, Vitola B. Prevalence and clinical significance of autoantibodies in children with overweight and obesity with nonalcoholic fatty liver disease. J Pediatr. 2021;239:155‐160.
Yodoshi T, Orkin S, Arce‐Clachar AC, et al. Significance of autoantibody seropositivity in children with obesity and non‐alcoholic fatty liver disease. Pediatric Obesity. 2021;16(1):e12696.
Wu H, Zhu L, Kinnear D, Triggs N, Quintanilla NM, Himes R. Clinical, laboratory, and histologic correlates of serum antinuclear antibody in hispanic pediatric patients with nonalcoholic fatty liver disease. Am J Clin Path. 2022;158(2):221‐227.
Rudolph B, Rivas Y, Kulak S, et al. Yield of diagnostic tests in obese children with an elevated alanine aminotransferase. Acta Paediatr (Stockholm). 2015;104(12):e557‐e563.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313‐1321.
Ravi S, Shoreibah M, Raff E, et al. Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis‐related liver disease. Dig Dis Sci. 2015;60(12):3788‐3793.
Vuppalanchi R, Gould RJ, Wilson LA, et al. Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int. 2012;6(1):379‐385.
Yodoshi T, Orkin S, Arce‐Clachar AC, et al. Alternative etiologies of liver disease in children with suspected NAFLD. Pediatrics. 2021;147(4):e2020009829.
Luo L, Ma Q, Lin L, Wang H, Ye J, Zhong B. Prevalence and significance of antinuclear antibodies in biopsy‐proven nonalcoholic fatty liver disease: a systematic review and meta‐analysis. Dis Markers. 2022;2022:1‐12.
Zhou YJ, Zheng KI, Ma HL, et al. Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy‐proven NAFLD. Nutr Metab Cardiovasc Dis. 2021;31(2):552‐560.